Endocrine Resistant Pik3ca Mutated Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Locally Advanced Or Metastatic Breast Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for endocrine resistant pik3ca mutated hormone receptor hr positive human epidermal growth factor receptor 2 her2 negative locally advanced or metastatic breast cancer. 14 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
14
Active US patents
52/100
Avg vulnerability
—
Annual revenue covered

Originators in Endocrine Resistant Pik3ca Mutated Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Locally Advanced Or Metastatic Breast Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Genentech Inc 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating endocrine resistant pik3ca mutated hormone receptor hr positive human epidermal growth factor receptor 2 her2 negative locally advanced or metastatic breast cancer. Each bar = one year. Y-axis scaled to peak year (6 patents).

4
30
6
36
4
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Itovebi
INAVOLISIB
 Genentech Inc 14 52 — 2030-09-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8343955 Itovebi method of use 81 2030-09-27
8343955 Itovebi method of use 81 2030-09-27
9650393 Itovebi method of use 75 2036-07-01
11760753 Itovebi method of use 75 2036-07-01
9650393 Itovebi method of use 75 2036-07-01
11760753 Itovebi method of use 75 2036-07-01
12410189 Itovebi method of use 75 2038-06-14
12410189 Itovebi method of use 75 2038-06-14
8242104 Itovebi composition of matter 23 2030-09-27
8242104 Itovebi composition of matter 23 2030-09-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11028100 Itovebi composition of matter 17 2038-04-26
11028100 Itovebi composition of matter 17 2038-04-26
10851091 Itovebi composition of matter 17 2036-07-01
10851091 Itovebi composition of matter 17 2036-07-01
8242104 Itovebi composition of matter 23 2030-09-27
8242104 Itovebi composition of matter 23 2030-09-27
12410189 Itovebi method of use 75 2038-06-14
12410189 Itovebi method of use 75 2038-06-14
11760753 Itovebi method of use 75 2036-07-01
9650393 Itovebi method of use 75 2036-07-01

Related